William Harvey Research Institute

Abstract Genetic variants that inactivate protein-coding genes are a powerful source of information about the phenotypic consequences of gene disruption: genes that are crucial for the function of an organism will be depleted of such variants in natural populations, whereas non-essential genes will tolerate their accumulation. However, predicted loss-of-function variants are enriched for annotation errors, and tend to be found at extremely low frequencies, so their analysis requires careful variant annotation and very large sample sizes 1 . Here we describe the aggregation of 125,748 exomes and 15,708 genomes from human sequencing studies into the Genome Aggregation Database (gnomAD). We identify 443,769 high-confidence predicted loss-of-function variants in this cohort after filtering for artefacts caused by sequencing and annotation errors. Using an improved model of human mutation rates, we classify human protein-coding genes along a spectrum that represents tolerance to inactivation, validate this classification using data from model organisms and engineered human cells, and show that it can be used to improve the power of gene discovery for both common and rare diseases.

There is increasing evidence that genome-wide association (GWA) studies represent a powerful approach to the identification of genes involved in common human diseases. We describe a joint GWA study (using the Affymetrix GeneChip 500K Mapping Array Set) undertaken in the British population, which has examined ∼2,000 individuals for each of 7 major diseases and a shared set of ∼3,000 controls. Case-control comparisons identified 24 independent association signals at P < 5 × 10-7: 1 in bipolar disorder, 1 in coronary artery disease, 9 in Crohn’s disease, 3 in rheumatoid arthritis, 7 in type 1 diabetes and 3 in type 2 diabetes. On the basis of prior findings and replication studies thus-far completed, almost all of these signals reflect genuine susceptibility effects. We observed association at many previously identified loci, and found compelling evidence that some loci confer risk for more than one of the diseases studied. Across all diseases, we identified a large number of further signals (including 58 loci with single-point P values between 10-5 and 5 × 10-7) likely to yield additional susceptibility loci. The importance of appropriately large samples was confirmed by the modest effect sizes observed at most loci identified. This study thus represents a thorough validation of the GWA approach. It has also demonstrated that careful use of a shared control group represents a safe and effective approach to GWA analyses of multiple disease phenotypes; has generated a genome-wide genotype database for future studies of common diseases in the British population; and shown that, provided individuals with non-European ancestry are excluded, the extent of population stratification in the British population is generally modest. Our findings offer new avenues for exploring the pathophysiology of these important disorders. We anticipate that our data, results and software, which will be widely available to other investigators, will provide a powerful resource for human genetics research. With the advent of many more markers in the human genome, it has become possible to search for genes associated with human disease without having to narrow down candidate regions of the genome first. In a ground-breaking publication, the Wellcome Trust Case Control Consortium reports an exciting genome-wide association study of some 17,000 individuals for seven common familial diseases. The analysis confirms previously identified loci and provides strong evidence for many novel disease susceptibility genes. An exciting genome-wide association study in the British population for seven common diseases. This analysis confirms previously identified loci and provides strong evidence for many novel disease susceptibility loci.

Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration (E&E) document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.

Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into two sets, the 'ARRIVE Essential 10', which constitutes the minimum requirement, and the 'Recommended Set', which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.

Improving the reproducibility of biomedical research is a major challenge. Transparent and accurate reporting is vital to this process; it allows readers to assess the reliability of the findings and repeat or build upon the work of other researchers. The ARRIVE guidelines (Animal Research: Reporting In Vivo Experiments) were developed in 2010 to help authors and journals identify the minimum information necessary to report in publications describing in vivo experiments. Despite widespread endorsement by the scientific community, the impact of ARRIVE on the transparency of reporting in animal research publications has been limited. We have revised the ARRIVE guidelines to update them and facilitate their use in practice. The revised guidelines are published alongside this paper. This explanation and elaboration document was developed as part of the revision. It provides further information about each of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence for their inclusion in the guidelines, elaboration of details to report, and examples of good reporting from the published literature. This document also covers advice and best practice in the design and conduct of animal studies to support researchers in improving standards from the start of the experimental design process through to publication.

Cyclooxygenase (COX), first purified in 1976 and cloned in 1988, is the key enzyme in the synthesis of prostaglandins (PGs) from arachidonic acid. In 1991, several laboratories identified a product from a second gene with COX activity and called it COX-2. However, COX-2 was inducible, and the inducing stimuli included pro-inflammatory cytokines and growth factors, implying a role for COX-2 in both inflammation and control of cell growth. The two isoforms of COX are almost identical in structure but have important differences in substrate and inhibitor selectivity and in their intracellular locations. Protective PGs, which preserve the integrity of the stomach lining and maintain normal renal function in a compromised kidney, are synthesized by COX-1. In addition to the induction of COX-2 in inflammatory lesions, it is present constitutively in the brain and spinal cord, where it may be involved in nerve transmission, particularly that for pain and fever. PGs made by COX-2 are also important in ovulation and in the birth process. The discovery of COX-2 has made possible the design of drugs that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1. These highly selective COX-2 inhibitors may not only be anti-inflammatory but may also be active in colon cancer and Alzheimer's disease.

OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.

Delineation of the left ventricular cavity, myocardium, and right ventricle from cardiac magnetic resonance images (multi-slice 2-D cine MRI) is a common clinical task to establish diagnosis. The automation of the corresponding tasks has thus been the subject of intense research over the past decades. In this paper, we introduce the "Automatic Cardiac Diagnosis Challenge" dataset (ACDC), the largest publicly available and fully annotated dataset for the purpose of cardiac MRI (CMR) assessment. The dataset contains data from 150 multi-equipments CMRI recordings with reference measurements and classification from two medical experts. The overarching objective of this paper is to measure how far state-of-the-art deep learning methods can go at assessing CMRI, i.e., segmenting the myocardium and the two ventricles as well as classifying pathologies. In the wake of the 2017 MICCAI-ACDC challenge, we report results from deep learning methods provided by nine research groups for the segmentation task and four groups for the classification task. Results show that the best methods faithfully reproduce the expert analysis, leading to a mean value of 0.97 correlation score for the automatic extraction of clinical indices and an accuracy of 0.96 for automatic diagnosis. These results clearly open the door to highly accurate and fully automatic analysis of cardiac CMRI. We also identify scenarios for which deep learning methods are still failing. Both the dataset and detailed results are publicly available online, while the platform will remain open for new submissions.

Macrophages are a diverse set of cells present in all body compartments. This diversity is imprinted by their ontogenetic origin (embryonal versus adult bone marrow-derived cells); the organ context; by their activation or deactivation by various signals in the contexts of microbial invasion, tissue damage, and metabolic derangement; and by polarization of adaptive T cell responses. Classic adaptive responses of macrophages include tolerance, priming, and a wide spectrum of activation states, including M1, M2, or M2-like. Moreover, macrophages can retain long-term imprinting of microbial encounters (trained innate immunity). Single-cell analysis of mononuclear phagocytes in health and disease has added a new dimension to our understanding of the diversity of macrophage differentiation and activation. Epigenetic landscapes, transcription factors, and microRNA networks underlie the adaptability of macrophages to different environmental cues. Macrophage plasticity, an essential component of chronic inflammation, and its involvement in diverse human diseases, most notably cancer, is discussed here as a paradigm.

Compared to other common complex diseases, it has proved remarkably difficult to establish the genetic basis of blood-pressure elevation. A multi-stage genome-wide association study involving 200,000 individuals of European descent provides some of the missing detail in the genetic picture. The study identified 16 relevant loci, of which only 6 contain genes previously known or suspected to regulate blood pressure. An association was found between hypertension, the thickness of the left ventricular wall, stroke and coronary artery disease, but not kidney disease or kidney function. Comparison with data from more than 75,000 people of East Asian, South Asian and African ancestries confirmed that many of the variants identified in European-ancestry subjects also influence blood pressure in other populations. Blood pressure is a heritable trait1 influenced by several biological pathways and responsive to environmental stimuli. Over one billion people worldwide have hypertension (≥140 mm Hg systolic blood pressure or ≥90 mm Hg diastolic blood pressure)2. Even small increments in blood pressure are associated with an increased risk of cardiovascular events3. This genome-wide association study of systolic and diastolic blood pressure, which used a multi-stage design in 200,000 individuals of European descent, identified sixteen novel loci: six of these loci contain genes previously known or suspected to regulate blood pressure (GUCY1A3–GUCY1B3, NPR3–C5orf23, ADM, FURIN–FES, GOSR2, GNAS–EDN3); the other ten provide new clues to blood pressure physiology. A genetic risk score based on 29 genome-wide significant variants was associated with hypertension, left ventricular wall thickness, stroke and coronary artery disease, but not kidney disease or kidney function. We also observed associations with blood pressure in East Asian, South Asian and African ancestry individuals. Our findings provide new insights into the genetics and biology of blood pressure, and suggest potential novel therapeutic pathways for cardiovascular disease prevention.

William harvey, when studying the circulation of the blood, must have recognized that "In sound and living vessels the blood remains fluid, but it coagulates in dead ones" (Ernst Brücke, 1857). Joseph Lister (1909) provided further evidence for an active role of blood vessels in maintaining the liquidity of blood. The vascular endothelium, which envelops the circulating blood in a continuous monolayer, is mainly responsible for this function.Over the past 20 years numerous other important functions have been discovered. For instance, the outer surface of the endothelial cell contains angiotensin-converting enzyme, which catalyzes the formation of the vasoconstrictor angiotensin . . .

An estimated 2.6 million third trimester stillbirths occurred in 2015 (uncertainty range 2.4-3.0 million). The number of stillbirths has reduced more slowly than has maternal mortality or mortality in children younger than 5 years, which were explicitly targeted in the Millennium Development Goals. The Every Newborn Action Plan has the target of 12 or fewer stillbirths per 1000 births in every country by 2030. 94 mainly high-income countries and upper middle-income countries have already met this target, although with noticeable disparities. At least 56 countries, particularly in Africa and in areas affected by conflict, will have to more than double present progress to reach this target. Most (98%) stillbirths are in low-income and middle-income countries. Improved care at birth is essential to prevent 1.3 million (uncertainty range 1.2-1.6 million) intrapartum stillbirths, end preventable maternal and neonatal deaths, and improve child development. Estimates for stillbirth causation are impeded by various classification systems, but for 18 countries with reliable data, congenital abnormalities account for a median of only 7.4% of stillbirths. Many disorders associated with stillbirths are potentially modifiable and often coexist, such as maternal infections (population attributable fraction: malaria 8.0% and syphilis 7.7%), non-communicable diseases, nutrition and lifestyle factors (each about 10%), and maternal age older than 35 years (6.7%). Prolonged pregnancies contribute to 14.0% of stillbirths. Causal pathways for stillbirth frequently involve impaired placental function, either with fetal growth restriction or preterm labour, or both. Two-thirds of newborns have their births registered. However, less than 5% of neonatal deaths and even fewer stillbirths have death registration. Records and registrations of all births, stillbirths, neonatal, and maternal deaths in a health facility would substantially increase data availability. Improved data alone will not save lives but provide a way to target interventions to reach more than 7000 women every day worldwide who experience the reality of stillbirth.

Summary Genetic variants that inactivate protein-coding genes are a powerful source of information about the phenotypic consequences of gene disruption: genes critical for an organism’s function will be depleted for such variants in natural populations, while non-essential genes will tolerate their accumulation. However, predicted loss-of-function (pLoF) variants are enriched for annotation errors, and tend to be found at extremely low frequencies, so their analysis requires careful variant annotation and very large sample sizes 1 . Here, we describe the aggregation of 125,748 exomes and 15,708 genomes from human sequencing studies into the Genome Aggregation Database (gnomAD). We identify 443,769 high-confidence pLoF variants in this cohort after filtering for sequencing and annotation artifacts. Using an improved human mutation rate model, we classify human protein-coding genes along a spectrum representing tolerance to inactivation, validate this classification using data from model organisms and engineered human cells, and show that it can be used to improve gene discovery power for both common and rare diseases.

Constitutive cyclooxygenase (COX-1; prostaglandin-endoperoxide synthase, EC 1.14.99.1) is present in cells under physiological conditions, whereas COX-2 is induced by some cytokines, mitogens, and endotoxin presumably in pathological conditions, such as inflammation. Therefore, we have assessed the relative inhibitory effects of some nonsteroidal antiinflammatory drugs on the activities of COX-1 (in bovine aortic endothelial cells) and COX-2 (in endotoxin-activated J774.2 macrophages) in intact cells, broken cells, and purified enzyme preparations (COX-1 in sheep seminal vesicles; COX-2 in sheep placenta). Similar potencies of aspirin, indomethacin, and ibuprofen against the broken cell and purified enzyme preparations indicated no influence of species. Aspirin, indomethacin, and ibuprofen were more potent inhibitors of COX-1 than COX-2 in all models used. The relative potencies of aspirin and indomethacin varied only slightly between models, although the IC50 values were different. Ibuprofen was more potent as an inhibitor of COX-2 in intact cells than in either broken cells or purified enzymes. Sodium salicylate was a weak inhibitor of both COX isoforms in intact cells and was inactive against COX in either broken cells or purified enzyme preparations. Diclofenac, BW 755C, acetaminophen, and naproxen were approximately equipotent inhibitors of COX-1 and COX-2 in intact cells. BF 389, an experimental drug currently being tested in humans, was the most potent and most selective inhibitor of COX-2 in intact cells. Thus, there are clear pharmacological differences between the two enzymes. The use of such models of COX-1 and COX-2 activity will lead to the identification of selective inhibitors of COX-2 with presumably less side effects than present therapies. Some inhibitors had higher activity in intact cells than against purified enzymes, suggesting that pure enzyme preparations may not be predictive of therapeutic action.

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Committee; LVH: left ventricular hypertrophy; LVM: left ventricular mass; PDE-5: phosphodiesterase-5; PPAR-γ: peroxisome proliferators-activated receptor-γ; PWV: pulse wave velocity; SBP: systolic blood pressure; WHO: World Health Organization. Introduction In the 2 years since the publication of the 2007 guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) [1], research on hypertension has actively been pursued and the results of new important studies (including several large randomized trials of antihypertensive therapy) have been published. Some of these studies have reinforced the evidence on which the recommendations of the 2007 ESH/ESC guidelines were based. However, other studies have widened the information available in 2007, modifying some of the previous concepts, and suggesting that new evidence-based recommendations could be appropriate. The aim of this document of the ESH is to address a number of studies on hypertension published in the last 2 years in order to assess their contribution to our expanding knowledge of hypertension. Furthermore, some critical appraisal of the current recommendations of the ESH/ESC, as well as of other guidelines, might be a useful step toward the preparation of a third version of the European guidelines in the future. The most important conclusions are summarized in boxes. The points that will be discussed are reported in Box 1.Box. 1Assessment of subclinical organ damage for stratification of total cardiovascular risk The 2007 ESH/ESC guidelines recommend total cardiovascular risk be evaluated in each patient to decide about important aspects of treatment: the blood pressure (BP) threshold at which to commence drug administration, the target BP to be reached by treatment, the use of two-drug combinations as the initial treatment step, and the possible addition to the antihypertensive treatment regimen of lipid-lowering and antiplatelet agents [1]. Among the criteria to assess total cardiovascular risk, the European guidelines consider subclinical organ damage to be a very important component, because asymptomatic alterations of the cardiovascular system and the kidney are crucial intermediate stages in the disease continuum that links risk factors such as hypertension to cardiovascular events and death. On the basis of a number of criteria (prognostic importance, prevalence in the population, availability and cost of the assessment procedures, etc.), the 2007 European guidelines considered detection of organ damage as important for the diagnostic and prognostic evaluation of hypertensive patients. They further subdivided the different types of organ damage into (1) those that can be identified by relatively simple and cheap procedures [electrocardiogram, serum creatinine, estimated glomerular filtration rate (eGFR), and measurement of urinary protein excretion in order to detect microalbuminuria or proteinuria], which were thus regarded as suitable for routine search in the whole hypertensive population, and (2) those that require more complex procedures or instrumentations (echocardiogram, carotid ultrasonography, pulse wave velocity), which were for this reason only recommended for a more in-depth characterization of the hypertensive patient. Since then, other studies have added useful information on the importance of detecting subclinical organ damage in the hypertensive population, strengthening the recommendation to use the most easily available and the least costly procedures in the routine examination of individuals with hypertension. Heart A few recent papers have revived interest in the of the to the risk of cardiovascular In a a new of left ventricular the of left ventricular that is on and has been reported to be to cardiovascular The for and Furthermore, in the the have reported that in hypertensive with left individuals at risk of cardiovascular cardiovascular and for a very recent on the in as with left ventricular and of cardiovascular events hypertension is by risk for each evidence is available on the of as by of interest because of to more and and A has information more and hypertensive with left ventricular left ventricular left ventricular in of the left ventricular and and the risk of as large as that of with left ventricular in on population, the left ventricular and for and only in the risk with has been by other In a on a of hypertensive for with a of and cardiovascular events and with for cardiovascular risk factors Furthermore, a of hypertensive in the that cardiovascular events about more in with a or more with those with a this in the population, with a to in cardiovascular and were for a large number of and BP A in the risk more risk the The of carotid and with cardiovascular discussed in the 2007 guidelines, has been further by which have that carotid cardiovascular events of BP and and this for the at the carotid and for the at the of the carotid that by the at the and by the carotid prognostic in addition to that of prognostic of carotid has been reported in a of of the of cardiovascular which for about years has on the prognostic of arterial In the population, pulse wave with a in the risk of a cardiovascular Furthermore, of for cardiovascular events has been in for years of and wave such as BP and have been as of cardiovascular events in recent studies In in of these studies of and hypertensive only and cardiovascular for cardiovascular risk and carotid However, be that in most available the of BP pressure which the BP be considered in the of hypertensive in of further new the evidence on the prognostic of that available at the of the 2007 guidelines [1]. In the of in the with a of cardiovascular events and in the and with a in the of and cardiovascular events for cardiovascular risk and of in a of the to the of and to the different and more of the to the which only of The by the to be of and cardiovascular events in the large number of 2 in the were for the urinary protein excretion of the risk of cardiovascular events the in the risk of cardiovascular and events and evidence is available to the large of in of the prognostic of the in urinary protein as microalbuminuria In the and the microalbuminuria as important of cardiovascular the and in with microalbuminuria with those In the the of microalbuminuria with a In the a of to the with a and in the risk of cardiovascular cardiovascular and this the the to microalbuminuria The of urinary protein excretion and were of each other and the of microalbuminuria and about in for cardiovascular for cardiovascular and for of organ damage The 2007 European guidelines a number of of organ damage for which evidence of prognostic use in the could be because of of such as the cost and availability of the the and in the procedures, and in several the of of the and on the evidence available in the last 2 addition to the of organ damage in the 2007 guidelines can be the availability of more and the cost of their use about by In this the use of in a very recent in a of hypertensive cardiovascular disease has the information that are more and subclinical and in the of other of organ damage evidence these to a of importance because of the of the more and more in diagnostic procedures, disease is to more in prognostic and studies in hypertension. The prognostic of alterations in has been by studies However, the of this measurement of this A new for the of for evaluation to be on a of a that has been actively in the In a of individuals cardiovascular disease with hypertension and with the of the of cardiovascular this of cardiovascular risk factors in the large of of the Health added very to the prognostic of risk factors On the have reported that in a of hypertensive for about of the the with a in cardiovascular events for cardiovascular risk However, the of have reported that in the of hypertensive of cardiovascular events because in different have a different prognostic the prognostic of in hypertension to be further be that the addition of new of organ damage to the assessment of total cardiovascular risk only the of their prognostic importance, has to the to the of cardiovascular is by to be and are available that in some new risk factors of prognostic added to the the by which cardiovascular risk can be thus only the diagnostic procedures more and is by the recent results of the which that of to in the and by which total cardiovascular risk organ damage as a of cardiovascular risk subclinical organ damage the of cardiovascular risk, the the patient into the that risk of at least cardiovascular events in years patients. The 2007 European guidelines hypertensive with subclinical organ damage those with a total cardiovascular is further by more recent evidence on the contribution of subclinical and damage to the total cardiovascular to subclinical of the by some of the studies that in hypertensive of the is with of cardiovascular events to or in years in years has been reported for for with in the in the hypertensive of the with a of cardiovascular events of with the in evidence for In the of the Health the of cardiovascular events the carotid or more and and in those with in the In the hypertensive of the the of and cardiovascular events in years carotid in the third and or at least been In with in the or the cardiovascular events in In hypertensive the of cardiovascular events or more and in those with in the and Furthermore, asymptomatic disease as by a has been to be in with of cardiovascular events in years and recent evidence that in hypertensive subclinical organ damage is with a risk of cardiovascular events of or has been reported some years that by a serum more is with a of cardiovascular events or more In the recent of hypertensive a with cardiovascular events of about in with Furthermore, in the hypertensive by the of disease in years in the of microalbuminuria and of only in in the the of cardiovascular events in only in those individuals in microalbuminuria in the with in the of these hypertension. The 2007 European guidelines with subclinical organ damage as at risk BP is in the evidence that this is the is In the of the information available on the prognostic of in the and hypertensive Furthermore, in the population, the of with cardiovascular events for cardiovascular risk BP In the microalbuminuria with only a cardiovascular in that a risk to the and in the individuals of the a microalbuminuria the with a rate of cardiovascular events of only in years with a rate in individuals with microalbuminuria the of of subclinical organ damage The 2007 European guidelines have that of organ damage the of cardiovascular that organ damage be to the in the in which hypertensive in treatment by of or a in cardiovascular those in or to that in and in other studies a in and or cardiovascular with in treatment or in with a of cardiovascular events and to Since 2007, on the in damage and cardiovascular have been by further of the which have that in left left ventricular and in of with cardiovascular rate Furthermore, have been that in in treatment cardiovascular the of in the carotid has for the been in a recent of to a of the of these with the large in to conclusions The of in with cardiovascular has been by some of the In this on a large number of or very cardiovascular risk the with a of angiotensin-converting and the in the on with or the other this by a in cardiovascular events and with in events However, these results the important that in can be a of the more or of treatment because for the results are in most a and few which in a very number of the that for that Furthermore, in the very cardiovascular risk the of the system by the and might have of that and the with a in In of this are some recent of the in with 2 In these of a with and cardiovascular the contribution of to the of on the important prognostic of subclinical organ damage to In hypertensive and the population, the of and a carotid or arterial a by the or microalbuminuria or the total cardiovascular risk, hypertensive into the risk The in or by treatment the on cardiovascular information on are more or by the treatment some recent results evidence that this is the for in urinary protein the for the of subclinical organ damage is of crucial importance in the hypertensive assessment can use of simple and cheap procedures that can routine information and at can on more that can further and In organ damage assessment is useful because of the evidence that in the of of organ damage to the cardiovascular risk be more with to the cardiovascular risk is published subclinical organ damage can total cardiovascular risk to the in with However, organ damage is or or is by risk is with a or in risk in individuals and the 2007 guidelines recommend risk as a for the of treatment in and patients. In this is important to that the of organ damage in that decide to the of several studies that the of cardiovascular events is in in hypertensive for cardiovascular risk factors and is with the that antihypertensive treatment a total risk to a the that in treatment is organ damage is use of organ damage assessment thus to a more about the of treatment and thus Some of the discussed in of subclinical organ damage for stratification of total cardiovascular risk are summarized in Box guidelines on the management of hypertension recommend the of antihypertensive in with a or more a or and to the treatment in order for the to be these They further recommend drug treatment to be a BP that a and and a and in with or a of cardiovascular or at The 2007 ESH/ESC guidelines have these recommendations with information on the evidence are and a critical of this has been by of the in the of further information by recent The of the ESH document is to the and the of evidence on which these recommendations are and thus the and of studies which possible evidence to antihypertensive treatment recommend use of antihypertensive in with hypertension at or cardiovascular risk, that BP is and and treatment has However, be that the evidence in of this recommendation is because trials of on BP could be those hypertension or the recent which in the 2007 guidelines to in with cardiovascular risk, evidence because BP a large of antihypertensive at and a number of evidence of organ damage or a of cardiovascular to the or that the BP threshold for drug treatment is to and recommend antihypertensive at at least or at least in the as However, as in is on hypertensive that with a in the hypertension can be that current guidelines recommendations on BP at which to drug treatment in the are on results other and by the large of antihypertensive in available trials in the at initial blood and at in antihypertensive treatment trials in the is for the guidelines recommendation to drug treatment in the BP have are on the results of the of the which has important as a the the the in and a of cardiovascular events in the randomized to more treatment to the of to other cardiovascular of large and However, in by BP were and the of cardiovascular in the in the of antihypertensive treatment in with or in those in this were stratification on the or of a of hypertension. have been recommendations to antihypertensive treatment at BP in with previous have been on the the that in with a previous or BP by a in the of and cardiovascular events in hypertensive and patients. However, in this hypertension by of or and in a a in with treatment only or more Furthermore, BP in were reported of treatment in of the and be to on of treatment in patients. the of evidence of has been by the results of a more recent large of antihypertensive treatment in with the these results be to a more in a more discussed in the 2007 European guidelines and further in a recent trials are available the information drug treatment be at BP in with disease is in most to the of the to the which were in these were subdivided for their or BP on a of antihypertensive drug administration, and thus the to a BP the results and trials pressure The evidence available on the BP of antihypertensive treatment has been by some of this and is summarized in in the in of trials in hypertensive to in the actively at or this in the or In of the BP with a in and in this for that were and the in a previous were at or cardiovascular risk and with this evidence the recommendation of guidelines to to in the of with or 2 hypertension and or total cardiovascular this recommendation to hypertensive is by in the of in trials the of hypertensive randomized to more treatment a of cardiovascular in the only with results the were to is evidence in of the guidelines recommendation to the target in patients. The of that the guidelines recommendation to BP in with or a of cardiovascular disease is by the recommendation in of treatment to the by some such as and a of cardiovascular for a BP in in hypertensive patients. in the of only in were and were with a in cardiovascular results trials in with a of or disease with the that in some trials in which to with the with of of trials and trials on organ damage on BP and for drug treatment has been of trials and studies on the of treatment on organ damage of prognostic importance, this is of the of cardiovascular events in to the BP by treatment have been in the large of hypertensive of the in the cardiovascular risk for the the and the and in the with of the In the the of cardiovascular events at a of and a of In the hypertensive in the BP a in the of cardiovascular events and with to the in BP these of the of treatment In the the of cardiovascular events as the of in which BP to be were for and The cardiovascular with a for cardiovascular events to as the to about On the in the of BP were initial were for were and at each initial a BP by a cardiovascular However, in in initial in the the and for have been reported for the of in in the with of the of to to cardiovascular and to of as well as in disease to the BP and subclinical organ the have that the of is to the BP by treatment, the for large BP the A published has that of is by as with BP and in hypertensive Furthermore, several studies have evidence that antihypertensive treatment is by a or a in urinary protein be in the or initial BP is The most recent evidence has been by the which has that in most of antihypertensive treatment, further BP by the addition of and the of of the the or the of urinary protein a of initial systolic or diastolic BP to The for a and in the actively as with the at initial or and Furthermore, this of the has the risk of a to as the treatment to of about The has been some a for of on the of some trials as well as of the results of other trials on have the that in at cardiovascular risk, antihypertensive treatment that to or and be by a further in the of that by a has to the as to BP is and in of cardiovascular The is to the a BP which organ is studies in of cardiovascular disease that the BP and cardiovascular rate is to very BP which are only by antihypertensive is possible that in cardiovascular risk of the that blood the BP threshold which organ is However, the of this be different in to the of organ damage and has been by trials to the of more BP for initial and of results the that in the in which BP could have been a initial cardiovascular risk that the BP and the of cardiovascular this is by the evidence of a in of several trials these the of cardiovascular by a of BP that is and and suggesting that this BP the in cardiovascular are is in with the results of studies that the BP and cardiovascular events is cardiovascular events are on a which at BP the 2007 recommendations the evidence is to in hypertensive at and risk, drug be BP to or a suitable with with the to BP this of antihypertensive treatment in hypertension for BP to to 2 or organ damage to is by a recent of trials with antihypertensive agents has that in trials on cardiovascular risk the that the risk by lipid-lowering and antiplatelet can very the a cardiovascular events in by a initial risk On the in trials hypertensive at initial or risk, the could be to in which that of antihypertensive be threshold and target for drug treatment in the the current availability of well BP to be with in or in cardiovascular or of antihypertensive drug in with BP is by is the for the BP recommended for in large and are more in the subclinical organ and microalbuminuria and to be the to decide the BP for treatment as well as treatment in patients. and at least the of studies such as which the of BP or are be useful to recommend that in be well that are be in with the results of the in which the and of antihypertensive treatment were in in to with on in at recommendations can be to with previous cardiovascular for current evidence is of antihypertensive drug treatment BP is in the and the of at a BP target of has been in those with a BP that the 2007 ESH/ESC guidelines as at cardiovascular risk because of the of risk or subclinical organ has been that this BP subclinical organ damage to a cardiovascular risk, and is this The evidence in of in these is to that reported by the and the studies in which of antihypertensive drug the of hypertension the of the this be pursued with or with addition of antihypertensive agents last recommendations for a number of of patient management randomized trials can only for a few years and of the results to the of is The to into that the of antihypertensive treatment more with because of organ damage has a in with the of large and with a BP to be by the results of the few trials in which were for a number of years of randomized In the and for the of antihypertensive treatment on the of cardiovascular events years of the of the the that antihypertensive treatment in the A which is to as the has been reported for the 2 which reported a on the and of 2 years of with that antihypertensive and in the a of the of a previous blood in The most important points to threshold and target BP for treatment are summarized in and of antihypertensive In their and 2007 [1], the European guidelines the large number of randomized trials of antihypertensive those treatment and those treatment on different They that the of antihypertensive treatment are to of BP and are of the well as and and can BP and and cardiovascular these are suitable for the and of antihypertensive treatment as or in some combinations with each of the of the of antihypertensive and of agents a has been a in the by the of a by in and in the with the as for and the of by their has been by different of on a possible of and as well as on the possible of for and of for disease to possible or of new and is of and and be by of guidelines On the be to of the of The evidence which have been as antihypertensive and in the recommendations discussed in the 2007 European on the of in antihypertensive have been added since In a of of randomized trials of a has been reported the rate by and cardiovascular the the the the of and to be by On the a recent of randomized trials only a of in with other a as other agents on events and and a other in with a recent Furthermore, the recent publication of a of the and in has the of cardiovascular to be in on the or the with a in the is with of large of on different antihypertensive treatment for in randomized that the of cardiovascular on treatment on other antihypertensive agents has been of the possible of a BP by treatment in those trials in which to have a on of on in the of the that the very to the because of the in and On the to be to other antihypertensive agents in their to A recent more hypertensive different has a of in However, studies for the be with with other antihypertensive agents because of a wave to to be on antihypertensive management be because the and is to at hypertension and antihypertensive treatment are most is that as well as have and in such as those with the or The importance of this have been by the results of most studies and trials have been that by of in or in to of or with a blood a recent of the has that new of at the of this in at are by a number of in which of at at the of the However, the for Furthermore, is the as with some studies that with have a of cardiovascular the and several years the conclusions in other studies is with other agents in trials subclinical organ damage as have been to be and in left ventricular carotid and and this be to in cardiovascular in the be that are a and that such as and to some of the for other and pulse pressure at the BP rate and because of the with has on BP In the on total and and at has been to and to have the as and have been in trials in in and of the of and in treatment by and in the the on or with in of microalbuminuria and to in hypertensive and has been to and left ventricular pressure in the hypertensive the cardiovascular by and in with is in hypertension to be in a A for in antihypertensive such as that to these in the is of The evidence that a BP by can types of cardiovascular events is be that most of the the of which has been the basis for on have to the of these drug the of and is to and has been have been in for their to organ and have been to or Furthermore, large studies that have the of of antihypertensive agents on to have to with the least or those by the least on treatment a recent has reported for for In the results of the be discussed in the drug combinations have as to are the of and The that be to other antihypertensive agents in has been on the basis of some and A to the that be to in has been On the has been that be to in these concepts, as well as their have been by the results of the very large cardiovascular treatment with or has to be to as as the of a are A of on and more recent trials the that and have the on The by the relatively BP by treatment is more to because in and for could a is to decide the has to be with the of the several years or with the of the on to The of with a of cardiovascular events in because prevalence of in to that in or because of a of and have some information on the of and on the of new in patients. the that has been to of new different and in and only and were in and in with to the However, most were other antihypertensive agents that have the of the these the that a have been the of a of events by the the On the some recent that these agents have some in is this can be to a or to a BP in the patients. is are in as is in several studies and large The recent by that trials in which a BP antihypertensive and the

BACKGROUND: The associations of blood pressure with the different manifestations of incident cardiovascular disease in a contemporary population have not been compared. In this study, we aimed to analyse the associations of blood pressure with 12 different presentations of cardiovascular disease. METHODS: We used linked electronic health records from 1997 to 2010 in the CALIBER (CArdiovascular research using LInked Bespoke studies and Electronic health Records) programme to assemble a cohort of 1·25 million patients, 30 years of age or older and initially free from cardiovascular disease, a fifth of whom received blood pressure-lowering treatments. We studied the heterogeneity in the age-specific associations of clinically measured blood pressure with 12 acute and chronic cardiovascular diseases, and estimated the lifetime risks (up to 95 years of age) and cardiovascular disease-free life-years lost adjusted for other risk factors at index ages 30, 60, and 80 years. This study is registered at ClinicalTrials.gov, number NCT01164371. FINDINGS: During 5·2 years median follow-up, we recorded 83,098 initial cardiovascular disease presentations. In each age group, the lowest risk for cardiovascular disease was in people with systolic blood pressure of 90-114 mm Hg and diastolic blood pressure of 60-74 mm Hg, with no evidence of a J-shaped increased risk at lower blood pressures. The effect of high blood pressure varied by cardiovascular disease endpoint, from strongly positive to no effect. Associations with high systolic blood pressure were strongest for intracerebral haemorrhage (hazard ratio 1·44 [95% CI 1·32-1·58]), subarachnoid haemorrhage (1·43 [1·25-1·63]), and stable angina (1·41 [1·36-1·46]), and weakest for abdominal aortic aneurysm (1·08 [1·00-1·17]). Compared with diastolic blood pressure, raised systolic blood pressure had a greater effect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressure had a greater effect on abdominal aortic aneurysm than did raised systolic pressure. Pulse pressure associations were inverse for abdominal aortic aneurysm (HR per 10 mm Hg 0·91 [95% CI 0·86-0·98]) and strongest for peripheral arterial disease (1·23 [1·20-1·27]). People with hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs) had a lifetime risk of overall cardiovascular disease at 30 years of age of 63·3% (95% CI 62·9-63·8) compared with 46·1% (45·5-46·8) for those with normal blood pressure, and developed cardiovascular disease 5·0 years earlier (95% CI 4·8-5·2). Stable and unstable angina accounted for most (43%) of the cardiovascular disease-free years of life lost associated with hypertension from index age 30 years, whereas heart failure and stable angina accounted for the largest proportion (19% each) of years of life lost from index age 80 years. INTERPRETATION: The widely held assumptions that blood pressure has strong associations with the occurrence of all cardiovascular diseases across a wide age range, and that diastolic and systolic associations are concordant, are not supported by the findings of this high-resolution study. Despite modern treatments, the lifetime burden of hypertension is substantial. These findings emphasise the need for new blood pressure-lowering strategies, and will help to inform the design of randomised trials to assess them. FUNDING: Medical Research Council, National Institute for Health Research, and Wellcome Trust.

The beneficial actions of nonsteroid anti-inflammatory drugs (NSAID) can be associated with inhibition of cyclo-oxygenase (COX)-2 whereas their harmful side effects are associated with inhibition of COX-1. Here we report data from two related assay systems, the human whole blood assay and a modified human whole blood assay (using human A549 cells as a source of COX-2). This assay we refer to as the William Harvey Modified Assay. Our aim was to make meaningful comparisons of both classical NSAIDs and newer COX-2-selective compounds. These comparisons of the actions of >40 NSAIDs and novel COX-2-selective agents, including celecoxib, rofecoxib and diisopropyl fluorophosphate, demonstrate a distribution of compound selectivities toward COX-1 that aligns with the risk of serious gastrointestinal complications. In conclusion, this full in vitro analysis of COX-1/2 selectivities in human tissues clearly supports the theory that inhibition of COX-1 underlies the gastrointestinal toxicity of NSAIDs in man.

The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.

Host-mediated lung inflammation is present1, and drives mortality2, in the critical illness caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development3. Here we report the results of the GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units. We have identified and replicated the following new genome-wide significant associations: on chromosome 12q24.13 (rs10735079, P = 1.65 × 10−8) in a gene cluster that encodes antiviral restriction enzyme activators (OAS1, OAS2 and OAS3); on chromosome 19p13.2 (rs74956615, P = 2.3 × 10−8) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3 (rs2109069, P = 3.98 × 10−12) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1 (rs2236757, P = 4.99 × 10−8) in the interferon receptor gene IFNAR2. We identified potential targets for repurposing of licensed medications: using Mendelian randomization, we found evidence that low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease; and transcriptome-wide association in lung tissue revealed that high expression of the monocyte–macrophage chemotactic receptor CCR2 is associated with severe COVID-19. Our results identify robust genetic signals relating to key host antiviral defence mechanisms and mediators of inflammatory organ damage in COVID-19. Both mechanisms may be amenable to targeted treatment with existing drugs. However, large-scale randomized clinical trials will be essential before any change to clinical practice. A genome-wide association study of critically ill patients with COVID-19 identifies genetic signals that relate to important host antiviral defence mechanisms and mediators of inflammatory organ damage that may be targeted by repurposing drug treatments.